Caseware UK (AP4) 2023.0.135 2023.0.135 2023-12-312023-12-312023-01-012No description of principal activityfalse2falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 12653358 2023-01-01 2023-12-31 12653358 2022-01-01 2022-12-31 12653358 2023-12-31 12653358 2022-12-31 12653358 c:Director1 2023-01-01 2023-12-31 12653358 c:Director2 2023-01-01 2023-12-31 12653358 c:RegisteredOffice 2023-01-01 2023-12-31 12653358 d:CurrentFinancialInstruments 2023-12-31 12653358 d:CurrentFinancialInstruments 2022-12-31 12653358 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 12653358 d:CurrentFinancialInstruments d:WithinOneYear 2022-12-31 12653358 d:ShareCapital 2023-12-31 12653358 d:ShareCapital 2022-12-31 12653358 d:RetainedEarningsAccumulatedLosses 2023-12-31 12653358 d:RetainedEarningsAccumulatedLosses 2022-12-31 12653358 c:FRS102 2023-01-01 2023-12-31 12653358 c:AuditExempt-NoAccountantsReport 2023-01-01 2023-12-31 12653358 c:FullAccounts 2023-01-01 2023-12-31 12653358 c:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 12653358 e:PoundSterling 2023-01-01 2023-12-31 iso4217:GBP xbrli:pure
Company registration number: 12653358







UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 DECEMBER 2023


BVBIOMEDICAL LIMITED






































img500d.png                        

 


BVBIOMEDICAL LIMITED
 


 
COMPANY INFORMATION


Directors
A A M Burns 
R A Garvin 




Registered number
12653358



Registered office
Magdalen Centre The Oxford Science Park
Robert Robinson Avenue

Oxford

OX4 4GA




Accountants
Menzies LLP
Chartered Accountants

3000a Parkway

Whiteley

Hampshire

PO15 7FX





 


BVBIOMEDICAL LIMITED
 



CONTENTS



Page
Statement of Financial Position
1 - 2
Notes to the Financial Statements
3 - 4


 


BVBIOMEDICAL LIMITED
REGISTERED NUMBER:12653358



STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2023

2023
2022
Note
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
727
160

Cash at bank and in hand
  
2,040
3,968

  
2,767
4,128

Creditors: amounts falling due within one year
 5 
(173,363)
(111,474)

Net current liabilities
  
 
 
(170,596)
 
 
(107,346)

Total assets less current liabilities
  
(170,596)
(107,346)

  

Net liabilities
  
(170,596)
(107,346)


Capital and reserves
  

Called up share capital 
  
1,000
1,000

Profit and loss account
  
(171,596)
(108,346)

  
(170,596)
(107,346)


Page 1

 


BVBIOMEDICAL LIMITED
REGISTERED NUMBER:12653358


    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2023

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




R A Garvin
Director

Date: 18 September 2024

The notes on pages 3 to 4 form part of these financial statements.

Page 2

 


BVBIOMEDICAL LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1.


General information

BVBiomedical Limited is a private company limited by share incorporated in England and Wales. The address of its registered office is disclosed on the company information page. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Going concern

At the balance sheet date the company's liabilities exceeding its assets. The directors will continue to support the company until the company starts to trade or receive income. On this basis the accounts have been prepared on the going concern basis.

 
2.3

Government grants

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to profit or loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.
Grants of a revenue nature are recognised in the Statement of Income and Retained Earnings in the same period as the related expenditure.

 
2.4

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.5

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.6

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.7

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Company's Statement of Financial Position when the Company becomes party to the contractual provisions of the instrument.

Page 3

 


BVBIOMEDICAL LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)


2.7
Financial instruments (continued)

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables due with the operating cycle fall into this category of financial instruments.


3.


Employees

The average monthly number of employees, including directors, during the year was 2 (2022 - 2).


4.


Debtors

2023
2022
£
£


Other debtors
727
-

Called up share capital not paid
-
160

727
160



5.


Creditors: Amounts falling due within one year

2023
2022
£
£

Other creditors
170,866
109,026

Accruals and deferred income
2,497
2,448

173,363
111,474



6.


Transactions with directors

At the period end the company owed the directors £170,866 (2022 - £109,026), included within other creditors. This amount is undated, unsecured and interest free.

 
Page 4